Knowledge and Uptake of Human Papillomavirus Vaccine among Female Adolescents in Port Harcourt. A Call for Urgent Intervention
Issue: 2023 - Volume 12 [Issue 1]
Ibinabo Laura Oboro *
College of Medical Sciences, Rivers State University, Port Harcourt, Nigeria.
Daprim Samuel Ogaji
Africa Centre of Excellence in Public Health and Toxicological Research, University of Port Harcourt, Nigeria.
*Author to whom correspondence should be addressed.
Background: Infection with high-risk types of the Human Papillomavirus (HPV) has been associated with the development of cancers in both genders, affecting the genital, oropharyngeal and anal regions. Safe and effective vaccines are available against high-risk types which are responsible for majority of cases of cervical cancer. This study was conducted to assess the level of knowledge and uptake of the HPV vaccine among female adolescents in Port Harcourt, Nigeria.
Methodology: A descriptive cross-sectional survey conducted among in-school female students of both public and private secondary schools in Port Harcourt metropolis, aged 9 - 19 years. A total of 328 participants were recruited using multi-stage sampling. Information on socio-demographics, sexual history, knowledge of HPV, its vaccine and vaccine uptake were collected using a self-administered, semi-structured questionnaire. Data was analyzed using SPSS version 23. Descriptive and analytical tests were performed to determine associations and predictors of vaccine uptake.
Results: The level of knowledge of the availability, protective role, and schedule for administration of the HPV vaccine was poor (≤36%). Only 2.1% of girls interviewed were vaccinated with 42.9% of these having taken only one dose, thus being incompletely vaccinated. The mean age at vaccine uptake was 13.4±1.2 years. The most common reason given for not having taken the vaccine, is unawareness of the vaccine (322/328). Uptake of the vaccine was better among students at public schools.
Conclusion: Social mobilization towards primary prevention of HPV infection should also focus on adolescents. Social media and school health programs/ clubs should be exploited/ improved to provide detailed and adolescent-friendly information necessary to stimulate improved uptake of the vaccine and thus reduce the devastating potential consequences of infection with the HPV.
Keywords: Adolescents, cervical cancer, Human Papillomavirus, Nigeria, vaccine
How to Cite
World Health Organization. Human Papilloma virus (HPV) and Cervical cancer; 2019. Available:https://www.who.int/news-room/fact-sheets/detail/human-Papilloma virus-(hpv)-and-cervical-cancer. Retrieved 15th May, 2021
Hausen HZ. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. Journal of the National Cancer Institute. 2000;92 (9):690-8.
Odaibo GN, Nejo YT, Olaleye DO. Prevalence and risk factors for genital human papillomavirus infections among women in Southwest Nigeria. Archives of Basic and Applied medicine. 2018;6(1): 105-12.
Kennedy NT, Ikechukwu D, Goddy B. Risk factors and distribution of oncogenic strains of human papilloma virus in women presenting for cervical cancer screening in Port Harcourt, Nigeria. Pan African Medical Journal. 2016;23(1).
Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, Smith JS, Arslan A, Munoz N, Snijders PJ. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. British Journal of Cancer. 2004;90(3):638-45.
Akarolo-Anthony SN, Famooto AO, Dareng EO, Olaniyan OB, Offiong R, Wheeler CM, Adebamowo CA. Age-specific prevalence of human papilloma virus infection among Nigerian women. BMC Public Health. 2014; 14:656. DOI: 10.1186/1471-2458-14-656
Chow LT, Broker TR, Steinberg BM. The natural history of human papillomavirus infections of the mucosal epithelia. Apmis. 2010;118(6‐7):422-49.
Collettini F, Hamm B. Cervical cancer. InMRI and CT of the Female Pelvis Springer, Cham. 2017;117-177.
Kahn JA. HPV vaccination for the prevention of cervical intraepithelial neoplasia. New England Journal of Medicine. 2009;361(3):271-8.
ICO/IARC Information Centre on HPV and Cancer. Nigeria: Human Papilloma virus and Related Cancers, Fact Sheet; 2021. Available:https://hpvcentre.net/statistics/reports/NGA_FS.pdf. Retrieved 15th October, 2021.
Toh ZQ, Kosasih J, Russell FM, Garland SM, Mulholland EK, Licciardi PV. Recombinant human papillomavirus nonavalent vaccine in the prevention of cancers caused by human papillomavirus. Infection and Drug Resistance. 2019;12: 1951.
Hampson IN, Oliver AW, Hampson L. Potential Effects of Human Papillomavirus Type Substitution, Superinfection Exclusion and Latency on the Efficacy of the Current L1 Prophylactic Vaccines. Viruses. 2020;13(1):22.
Cervantes JL, Doan AH. Discrepancies in the evaluation of the safety of the human papillomavirus vaccine. Memórias do Instituto Oswaldo Cruz. 2018;113.
American College of Obstetricians and Gynaecologists. Human Papillomavirus Vaccination; 2021. Available:https://www.acog.org/clinical/clinical-guidance/committee-opinion/ articles/2020/08/human-papillomavirus-vaccination. Accessed 18th October, 2022.
World Health Organization. Human Papilloma virus (HPV) and cervical cancer; 2021. Available:https://www.who.int/news-room/ fact-sheets/detail/human-Papilloma virus-(hpv)-and-cervical-cancer.Accessed October 27th, 2021.
Yusupov A, Popovsky D, Mahmood L, Kim AS, Akman AE, Yuan H. The nonavalent vaccine: A review of high-risk HPVs and a plea to the CDC. American Journal of Stem Cells. 2019;8(3):52.
Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines. 2021;9(12):1413.
Toft L, Tolstrup M, Müller M, Sehr P, Bonde J, Storgaard M, et al. Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV- infected adults. Human Vaccines & Immunotherapeutics. 2014;10(5): 1147-54.
Wheeler CM, Castellsagué X, Garland SM, Szarewski A, Paavonen J, Naud P, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. The Lancet Oncology. 2012;13(1):100-10.
Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecologic oncology. 2007;107(2):S31-3.
Schiffman M, Wentzensen N. Human papillomavirus infection and the multistage carcinogenesis of cervical cancer. Cancer Epidemiology, Biomarkers & Prevention. 2013;22(4):553-60.
World Health Organization. Human Papilloma virus vaccines (HPV); 2021. Available:https://www.who.int/teams/immunization-vaccines-and-biologicals/ diseases/human-Papilloma virus-vaccines-(HPV). Accessed October 7th, 2021.
Dunsne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS, et al. Prevalence of HPV infection among females in the United States. JAMA. 2007 Feb 28;297(8):813-9.
Centers for Disease Control and Prevention, 2021. HPV vaccination is safe and effective. Available at https://www.cdc.gov/hpv/parents/vaccinesafety.html. Retrieved October 7th, 2021.
Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, et al. The biology and life cycle of human papillomaviruses. Vaccine 30. (Suppl 5): F55–F70.
Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Preventive Medicine. 2021; 144:106399.
Seid MA, Hussen MS. Knowledge and attitude towards antimicrobial resistance among final year undergraduate paramedical students at University of Gondar, Ethiopia. BMC Infectious Diseases. 2018;18(1):1-8.
Oboro IL, Athanasius BP. Awareness of Cervical Cancer Screening and Prevention among Students of a Tertiary Institution in Southern Nigeria. Breast Cancer. 2020; 2:3.
Gualano MR, Stillo M, Mussa MV, Zotti CM. Cross sectional study investigating the differences in knowledge and behaviors about HPV between vaccinated and non-vaccinated girls. Journal of Preventive Medicine and Hygiene. 2016; 57(3):E121.
Santos AC, Silva NN, Carneiro CM, Coura-Vital W, Lima AA. Knowledge about cervical cancer and HPV immunization dropout rate among Brazilian adolescent girls and their guardians. BMC Public Health. 2020 Dec;20(1):1-1.
Kress CM, Sharling L, Owen-Smith AA, Desalegn D, Blumberg HM, Goedken J. Knowledge, attitudes, and practices regarding cervical cancer and screening among Ethiopian health care workers. International Journal of Women's Health. 2015;7:765.
Zahedi L, Sizemore E, Malcolm S, Grossniklaus E, Nwosu O. Knowledge, attitudes and practices regarding cervical cancer and screening among Haitian health care workers. International Journal of Environmental Research and Public Health. 2014;11(11):11541-52.
Bisi-Onyemaechi AI, Chikani UN, Nduagubam O. Reducing incidence of cervical cancer: knowledge and attitudes of caregivers in Nigerian city to human papilloma virus vaccination. Infectious Agents and Cancer. 2018;13(1):1-6.
Alice S, Reuben K, Gabriel CM, Salimin AH. Effects of Covid-19 pandemic on religious activities and faith of worshippers in Kenya; A case study of Narok Town, Kenya. Journal of Studies in Social Sciences. 2021;20.
LeDoux J, Mann C, Demoratz M, Young J. Addressing spiritual and religious influences in care delivery. Professional Case Management. 2019;24(3): 142-7.